Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 10/2013

01-10-2013 | Original Paper

TIS21/BTG2 inhibits invadopodia formation by downregulating reactive oxygen species level in MDA-MB-231 cells

Authors: Jung-A. Choi, In Kyoung Lim

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2013

Login to get access

Abstract

Purpose

Invasion of cancer cells depends on the proteolytic degradation of extracellular matrix regulated by actin-driven membrane protrusions, called invadopodia. However, the mechanisms underlying invadopodia formation in cancer cells remain largely unknown.

Methods

By employing adenoviral transduction of breast cancer cells with either β-galactosidase (Ad-LacZ) or TIS21/BTG2/Pc3 (Ad-TIS21) gene, the regulation of invadopodia formation was investigated. Invasion activity was examined by invadopodia assay and Matrigel assay. Intracellular reactive oxygen species (ROS) was monitored by FACS-based analysis.

Results

Here, we observed that TIS21 suppressed invadopodia formation as well as invasion activity along with F-actin remodeling. The inhibition of TIS21-mediated invadopodia formation was accompanied with attenuation of ROS generation in the TIS21 expressers, indicating that TIS21-mediated inhibition of ROS plays a critical role for invadopodia formation by regulating actin-associated protein remodeling. This was further confirmed in the TIS21−/−MEF cells.

Conclusions

This is the first report to provide insight into invasion signals regulated by tumor suppressor, TIS21/BTG2/Pc3 gene, in the intractable breast cancer cells.
Appendix
Available only for authorised users
Literature
Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller FC et al (2006) Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66:3034–3043PubMedCrossRef
Ben Mahdi MH, Andrieu V, Pasquier C (2000) Focal adhesion kinase regulation by oxidative stress in different cell types. IUBMB Life 50:291–299PubMedCrossRef
Bradbury A, Possenti R, Shooter EM et al (1991) Molecular cloning of PC3, a putatively secreted protein whose mRNA is induced by nerve growth factor and depolarization. Proc Natl Acad Sci USA 88:3353–3357PubMedCrossRef
Buccione R, Orth JD, McNiven MA (2004) Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nat Rev Mol Cell Biol 5:647–657PubMedCrossRef
Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572PubMedCrossRef
Chiarugi P, Pani G, Giannoni E et al (2003) Reactive oxygen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion. J Cell Biol 161:933–944PubMedCrossRef
Clark ES, Whigham AS, Yarbrough WG et al (2007) Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res 67:4227–4235PubMedCrossRef
Coopman PJ, Do MT, Thompson EW et al (1998) Phagocytosis of cross-linked gelatin matrix by human breast carcinoma cells correlates with their invasive capacity. Clin Cancer Res 4:507–515PubMed
Diaz B, Shani G, Pass I et al (2009) Tks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci Signal 2:ra53PubMedCrossRef
Eckert MA, Lwin TM, Chang AT et al (2011) Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 19:372–386PubMedCrossRef
Farioli-Vecchioli S, Cinà I, Ceccarelli M et al (2012) TIS21 knock-out enhances the frequency of medulloblastoma in Patched1 heterozygous mice by inhibiting the Cxcl3-dependent migration of cerebellar neurons. J Neurosci 32:15547–15564PubMedCrossRef
Ficazzola MA, Fraiman M, Gitlin J et al (2001) Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis. Carcinogenesis 22:1271–1279PubMedCrossRef
Fletcher BS, Lim RW, Varnum BC et al (1991) Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters. J Biol Chem 266:14511–14518PubMed
Kawakubo H, Brachtel E, Hayashida T et al (2006) Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res 66:7075–7082PubMedCrossRef
Lim IK (2006) TIS21(/BTG2/PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule. J Cancer Res Clin Oncol 132:417–426PubMedCrossRef
Lim IK, Lee MS, Lee SH et al (1995) Differential expression of TIS21 and TIS1 genes in the various organs of Balb/c mice, thymic carcinoma tissues and human cancer cell lines. J Cancer Res Clin Oncol 121:279–284PubMedCrossRef
Linder S, Aepfelbacher M (2003) Podosomes: adhesion hot-spots of invasive cells. Trends Cell Biol 13:376–385PubMedCrossRef
Mader CC, Oser M, Magalhaes MA et al (2011) An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res 71:1730–1741PubMedCrossRef
Matsuda S, Rouault J, Magaud J et al (2001) In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett 497:67–72PubMedCrossRef
Melamed J, Kernizan S, Walden PD (2002) Expression of B-cell translocation gene 2 protein in normal human tissues. Tissue Cell 34:28–32PubMedCrossRef
Park S, Lee YJ, Lee HJ et al (2004) B-cell translocation gene 2 (Btg2) regulates vertebral patterning by modulating bone morphogenetic protein/smad signaling. Mol Cell Biol 24:10256–10262PubMedCrossRef
Park TJ, Kim JY, Oh SP et al (2008) TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop. Hepatology 47:1533–1543PubMedCrossRef
Rouault JP, Falette N, Guéhenneux F et al (1996) Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 14:482–486PubMedCrossRef
Schmidt M, Böhm D, von Törne C et al (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68:5405–5413PubMedCrossRef
Struckmann K, Schraml P, Simon R et al (2004) Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. Cancer Res 64:1632–1638PubMedCrossRef
Stylli SS, Kaye AH, Lock P (2008) Invadopodia: at the cutting edge of tumour invasion. J Clin Neurosci 15:725–737PubMedCrossRef
Takahashi F, Chiba N, Tajima K et al (2011) Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. Oncogene 30:3084–3095PubMedCrossRef
Tobar N, Cáceres M, Santibáñez JF et al (2008) RAC1 activity and intracellular ROS modulate the migratory potential of MCF-7 cells through a NADPH oxidase and NFkappaB-dependent mechanism. Cancer Lett 267:125–132PubMedCrossRef
Turner DP, Moussa O, Sauane M et al (2007) Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res 67:1618–1625PubMedCrossRef
van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRef
Yamaguchi H, Lorenz M, Kempiak S et al (2005a) Molecular mechanisms of invadopodium formation: the role of the N-WASP–Arp2/3 complex pathway and cofilin. J Cell Biol 168:441–452PubMedCrossRef
Yamaguchi H, Wyckoff J, Condeelis J (2005b) Cell migration in tumors. Curr Opin Cell Biol 17:559–564PubMedCrossRef
Yamaguchi H, Takeo Y, Yoshida S et al (2009) Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. Cancer Res 69:8594–8602PubMedCrossRef
Metadata
Title
TIS21/BTG2 inhibits invadopodia formation by downregulating reactive oxygen species level in MDA-MB-231 cells
Authors
Jung-A. Choi
In Kyoung Lim
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 10/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-013-1484-3

Other articles of this Issue 10/2013

Journal of Cancer Research and Clinical Oncology 10/2013 Go to the issue

Original Paper

A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy

Erratum

Erratum to: Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component

Review

MicroRNAs targeting EGFR signalling pathway in colorectal cancer

Original Paper

Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors

Original Paper

Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer

Original Paper

Expression of E-cadherin, Twist, and p53 and their prognostic value in patients with oral squamous cell carcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits